Grufity logo
Grufity logo
TRVI

TRVI - Trevi Therapeutics Inc Stock Price, Fair Value and News

$15.91-0.73 (-4.39%)
Market Closed as of 10 Sep 2026, 04:00 pm ET

Price Targets

TRVI Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

TRVI Price Action

Last 7 days

-6.7%

Last 30 days

-10.6%

Last 90 days

12.0%

Trailing 12 Months

65.4%

TRVI RSI Chart

TRVI Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

TRVI Valuation

Market Cap

2.3B

Price/Earnings (Trailing)

-44.35

EV/EBITDA

-43.35

Price/Free Cashflow

-42.88

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

TRVI Fundamentals

TRVI Earnings

Earnings (TTM)

-51.1M

Earnings Growth (Yr)

-44.68%

Earnings Growth (Qtr)

-34.91%

TRVI Profitability

Return on Equity

-15.9%

Return on Assets

-15.46%

Free Cashflow Yield

-2.33%

TRVI Investor Care

Shares Dilution (1Y)

17.00%

Diluted EPS (TTM)

-0.34

Revenue & Growth

How Trevi Therapeutics Inc generates revenue and covers its expenses, based on the latest reported earnings.

About Trevi Therapeutics Inc

TRVI
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio for the treatment of serious cough conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b/3 clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.
 CEO
 WEBSITEtrevitherapeutics.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES30

Trevi Therapeutics Inc Frequently Asked Questions

TRVI is the stock ticker symbol of Trevi Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Thu Sep 10 2026, market cap of Trevi Therapeutics Inc is 2.27 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.